Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Fineline Cube Mar 31, 2026
Company Deals

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Fineline Cube Mar 31, 2026
Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026
Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

Fineline Cube Mar 31, 2026
Company Drug

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

Fineline Cube Mar 31, 2026
Company Deals

Lee’s Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions

Fineline Cube Jul 31, 2025

China-based Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced on July 28, 2025, that it has...

Company

GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines

Fineline Cube Jul 31, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales...

Company Deals

CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086

Fineline Cube Jul 31, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced today that it has entered into an...

Company Drug

HRAIN Biotech’s HICARA Approved by NMPA for Relapsed/Refractory LBCL

Fineline Cube Jul 31, 2025

The National Medical Products Administration (NMPA) officially approved the New Drug Application (NDA) for lenecabtagene...

Company Drug

Eli Lilly’s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial

Fineline Cube Jul 30, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that...

Company Drug

Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials

Fineline Cube Jul 30, 2025

Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) announced that it has received...

Company Drug

Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment

Fineline Cube Jul 30, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing...

Company Deals

LTZ Therapeutics and Eli Lilly Partner to Develop Myeloid Engager Therapeutics

Fineline Cube Jul 30, 2025

LTZ Therapeutics and Eli Lilly (NYSE: LLY) announced a significant strategic collaboration on July 29,...

Company Drug

Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01

Fineline Cube Jul 30, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...

Others

China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment

Fineline Cube Jul 30, 2025

China Medical System Holdings Ltd (CMS; HKG: 0867, SGX: 8A8) announced on July 28, 2025,...

Company

MSD’s Q2 Earnings Hit by Gardasil Sales Decline, Keytruda Growth Slows

Fineline Cube Jul 30, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced its Q2 2025 financial results,...

Company

Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered

Fineline Cube Jul 30, 2025

Shares of Denmark-based biopharma giant Novo Nordisk A/S (NYSE: NVO) dipped over 20% during trading...

Company Drug

YolTech’s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment

Fineline Cube Jul 29, 2025

China-based YolTech Therapeutics announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products...

Company Drug

Cedicine Biotech’s Umbilical Cord Blood Mononuclear Cell Injection Gains CDE Approval for Clinical Trial

Fineline Cube Jul 29, 2025

China-based Cedicine Biotechnology announced today that the Center for Drug Evaluation (CDE) of the National...

Company Drug

Alphamab Oncology’s JSKN003 Granted FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer

Fineline Cube Jul 29, 2025

China-based Alphamab Oncology (HKG: 9966) announced today that its drug candidate JSKN003 has received Orphan...

Company Drug

Pierre Fabre’s Braftovi Approved in China for BRAF V600E-mutant Metastatic Colorectal Cancer

Fineline Cube Jul 29, 2025

France-based Pierre Fabre Laboratories announced that Braftovi (encorafenib) in combination with cetuximab has been approved...

Company Drug

Henlius Biotech’s HLX14 Recommended for EU Approval by EMA’s CHMP

Fineline Cube Jul 29, 2025

China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) announced on July 28, 2025, that the European...

Company Deals

Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer’s Treatment

Fineline Cube Jul 29, 2025

China-based Fosun Pharmaceutical (SHA: 600196) announced that its controlling subsidiary, Fosun Pharma Industrial, has entered...

Company Deals

Boehringer Ingelheim and Re-Vana Partner to Develop First-in-Class Ocular Therapies

Fineline Cube Jul 29, 2025

German pharmaceutical giant Boehringer Ingelheim (BI) today announced a strategic collaboration and licensing agreement with...

Company Deals

Tigermed Acquires Japan’s Micron CRO to Expand Imaging Expertise in Asia-Pacific

Fineline Cube Jul 29, 2025

China-based Tigermed (SHE: 300347, HKG: 3347) announced on July 29, 2025, that it has completed...

Posts pagination

1 … 99 100 101 … 644

Recent updates

  • Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors
  • Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures
  • Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs
  • Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor
  • Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology/CNS Segment Strength
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Company Medical Device

Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures

Company Deals

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Company Drug

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.